Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | NPY1R | P25929 | 1/20 | 0.39 |
| ▸ | NPY2R | P49146 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | PDE7A | Q13946 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30103271 | 0.78 | PRKD1 (0.49) | RAB9ANPC1POLBMAPTALDH1A1 | |
| SCHEMBL23958135 | 0.78 | PRKD1 (0.49) | RAB9ANPC1POLBMAPTALDH1A1 | |
| SCHEMBL23931384 | 0.78 | PRKD1 (0.49) | RAB9ANPC1POLBMAPTALDH1A1 | |
| SCHEMBL24111019 | 0.77 | MAPT (0.47) | RAB9ANPC1POLBMAPTALDH1A1 | |
| SCHEMBL24089980 | 0.76 | ALDH1A1 (0.51) | RAB9ANPC1POLBMAPTALDH1A1 | |
| SCHEMBL24110933 | 0.74 | MAPT (0.41) | RAB9ANPC1POLBMAPTALDH1A1 | |
| SCHEMBL23958271 | 0.73 | MAPT (0.43) | RAB9ANPC1POLBMAPTALDH1A1 | |
| SCHEMBL23958274 | 0.72 | TP53 (0.43) | POLBMAPTLMNAPDE7A | |
| SCHEMBL24110980 | 0.71 | MAPT (0.45) | MAPTALDH1A1KDM4EPDE7AHSD17B10 | |
| SCHEMBL23958173 | 0.70 | ALDH1A1 (0.48) | RAB9ANPC1POLBMAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210387967-A1 | 2-HETEROARYL AMINOQUINAZOLINONE DERIVATIVE | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2021-12-16 | — | — | US | disclosed |
| WO-2021215537-A1 | 2-HETEROARYLAMINOQUINAZOLINONE DERIVATIVE | 大日本住友製薬株式会社 (JP) | 2021-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210387967-A1 | 2-HETEROARYL AMINOQUINAZOLINONE DERIVATIVE | CRKL, CLIC4, CLIC1 | RAB9A 2222/4885NPC1 979/4885POLB 4618/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.